Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Peptic Ulcer

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 74 articles:
HTML format



Single Articles


    July 2021
  1. PATEL J, Berezowski I, Janapala RN, Pourmand A, et al
    Proton pump inhibitors and gastric cancer: a population-based cohort study.
    Gut. 2021 Jul 14. pii: gutjnl-2021-325385. doi: 10.1136/gutjnl-2021-325385.
    PubMed    


  2. OSTER P, Vaillant L, Riva E, McMillan B, et al
    Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies.
    Gut. 2021 Jul 12. pii: gutjnl-2020-323392. doi: 10.1136/gutjnl-2020-323392.
    PubMed     Abstract available


  3. ABRAHAMI D, McDonald EG, Schnitzer ME, Barkun AN, et al
    Proton pump inhibitors and risk of gastric cancer: population-based cohort study.
    Gut. 2021 Jul 5. pii: gutjnl-2021-325097. doi: 10.1136/gutjnl-2021-325097.
    PubMed     Abstract available


  4. ABRAHAMI D, McDonald EG, Schnitzer ME, Barkun AN, et al
    Proton pump inhibitors and risk of colorectal cancer.
    Gut. 2021 Jul 1. pii: gutjnl-2021-325096. doi: 10.1136/gutjnl-2021-325096.
    PubMed     Abstract available


    June 2021
  5. ONG JS, An J, Han X, Law MH, et al
    Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett's oesophagus and provides insights into clinical heterogeneity in reflux diagnosis.
    Gut. 2021 Jun 29. pii: gutjnl-2020-323906. doi: 10.1136/gutjnl-2020-323906.
    PubMed     Abstract available


    May 2021
  6. SEO SI, Park CH, You SC, Kim JY, et al
    Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea.
    Gut. 2021 May 11. pii: gutjnl-2020-323845. doi: 10.1136/gutjnl-2020-323845.
    PubMed     Abstract available


    April 2021
  7. MEGRAUD F, Bruyndonckx R, Coenen S, Wittkop L, et al
    Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community.
    Gut. 2021 Apr 9. pii: gutjnl-2021-324032. doi: 10.1136/gutjnl-2021-324032.
    PubMed     Abstract available


    March 2021
  8. SUNG JJY, Laine L, Kuipers EJ, Barkun AN, et al
    Towards personalised management for non-variceal upper gastrointestinal bleeding.
    Gut. 2021 Mar 1. pii: gutjnl-2020-323846. doi: 10.1136/gutjnl-2020-323846.
    PubMed     Abstract available


    December 2020
  9. SPILLER RC, Jalanka J
    Brachyspira and IBS with diarrhoea: a Helicobacter pylori moment?
    Gut. 2020 Dec 24. pii: gutjnl-2020-323370. doi: 10.1136/gutjnl-2020-323370.
    PubMed    


  10. HE Q, Yang M, Qin X, Fan D, et al
    Risk stratification for proton pump inhibitor-associated type 2 diabetes: a population-based cohort study.
    Gut. 2020 Dec 22. pii: gutjnl-2020-323816. doi: 10.1136/gutjnl-2020-323816.
    PubMed    


  11. LU TX, Dapas M, Lin E, Peters T, et al
    The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies.
    Gut. 2020 Dec 17. pii: gutjnl-2020-321609. doi: 10.1136/gutjnl-2020-321609.
    PubMed     Abstract available


  12. LEE SW, Yang JM, Yoo IK, Moon SY, et al
    Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort.
    Gut. 2020 Dec 10. pii: gutjnl-2020-323672. doi: 10.1136/gutjnl-2020-323672.
    PubMed    


  13. ZHOU J, Wang X, Lee S, Wu WKK, et al
    Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study.
    Gut. 2020 Dec 4. pii: gutjnl-2020-323668. doi: 10.1136/gutjnl-2020-323668.
    PubMed    


    November 2020
  14. LI GF, An XX, Yu Y, Jiao LR, et al
    Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis.
    Gut. 2020 Nov 10. pii: gutjnl-2020-323366. doi: 10.1136/gutjnl-2020-323366.
    PubMed    


    October 2020
  15. LIOU JM, Malfertheiner P, Lee YC, Sheu BS, et al
    Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus.
    Gut. 2020 Oct 1. pii: gutjnl-2020-322368. doi: 10.1136/gutjnl-2020-322368.
    PubMed     Abstract available


    September 2020
  16. ZHOU X, Zhu H, Chen Y, Li Z, et al
    Role of Helicobacter pylori in gastric diseases pathogenesis cannot be ignored.
    Gut. 2020 Sep 29. pii: gutjnl-2020-322629. doi: 10.1136/gutjnl-2020-322629.
    PubMed    


  17. YUAN J, He Q, Nguyen LH, Wong MCS, et al
    Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies.
    Gut. 2020 Sep 28. pii: gutjnl-2020-322557. doi: 10.1136/gutjnl-2020-322557.
    PubMed     Abstract available


  18. NYSSEN OP, Bordin D, Tepes B, Perez-Aisa A, et al
    European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients.
    Gut. 2020 Sep 21. pii: gutjnl-2020-321372. doi: 10.1136/gutjnl-2020-321372.
    PubMed     Abstract available


  19. GRAHAM DY, El-Serag HB
    European Registry on Helicobacter pylori management shows that gastroenterology has largely failed in its efforts to guide practitioners.
    Gut. 2020 Sep 21. pii: gutjnl-2020-322385. doi: 10.1136/gutjnl-2020-322385.
    PubMed    


  20. WU CY, Ho HJ, Wu CY, Chen YJ, et al
    Association between proton pump inhibitor use and mortality in patients with hepatocellular carcinoma receiving tyrosine kinase inhibitor.
    Gut. 2020 Sep 9. pii: gutjnl-2020-321932. doi: 10.1136/gutjnl-2020-321932.
    PubMed    


    August 2020
  21. CHIANG TH, Chang WJ, Chen SL, Yen AM, et al
    Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands.
    Gut. 2020 Aug 13. pii: gutjnl-2020-322200. doi: 10.1136/gutjnl-2020-322200.
    PubMed     Abstract available


    July 2020
  22. EUSEBI LH, Cirota GG, Zagari RM, Ford AC, et al
    Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis.
    Gut. 2020 Jul 30. pii: gutjnl-2020-321365. doi: 10.1136/gutjnl-2020-321365.
    PubMed     Abstract available


  23. LEE SW, Ha EK, Yeniova AO, Moon SY, et al
    Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching.
    Gut. 2020 Jul 30. pii: gutjnl-2020-322248. doi: 10.1136/gutjnl-2020-322248.
    PubMed     Abstract available


    May 2020
  24. ROGERS BD, Valdovinos LR, Crowell MD, Bell R, et al
    Number of reflux episodes on pH-impedance monitoring associates with improved symptom outcome and treatment satisfaction in gastro-oesophageal reflux disease (GERD) patients with regurgitation.
    Gut. 2020 May 28. pii: gutjnl-2020-321395. doi: 10.1136/gutjnl-2020-321395.
    PubMed     Abstract available


    April 2020
  25. XIONG J, Wang Y, Chen G, Jin L, et al
    Proton pump inhibitors and the risk of gallbladder cancer: a hospital-based case-control study.
    Gut. 2020 Apr 9. pii: gutjnl-2020-321052. doi: 10.1136/gutjnl-2020-321052.
    PubMed    


  26. WONG GLH, Lau LHS, Ching JYL, Tse YK, et al
    Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial.
    Gut. 2020;69:652-657.
    PubMed     Abstract available


    March 2020
  27. FORD AC, Yuan Y, Moayyedi P
    Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis.
    Gut. 2020 Mar 23. pii: gutjnl-2020-320839. doi: 10.1136/gutjnl-2020-320839.
    PubMed     Abstract available


  28. YAMAJI Y, Hirata Y
    Treatment for Helicobacter pylori appears to reduce the incidence of gastric cancer: eradication effect or screening effect?
    Gut. 2020;69:605-606.
    PubMed    


    January 2020
  29. TAO ZH, Fang JY
    The complicated dialogue between Helicobacter pylori and p53.
    Gut. 2020 Jan 23. pii: gutjnl-2020-320630. doi: 10.1136/gutjnl-2020-320630.
    PubMed    


  30. SUNG JJY, Coker OO, Chu E, Szeto CH, et al
    Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication.
    Gut. 2020 Jan 23. pii: gutjnl-2019-319826. doi: 10.1136/gutjnl-2019-319826.
    PubMed     Abstract available


  31. SUZUKI S, Gotoda T, Kusano C, Ikehara H, et al
    Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan.
    Gut. 2020 Jan 8. pii: gutjnl-2019-319954. doi: 10.1136/gutjnl-2019-319954.
    PubMed     Abstract available


    December 2019
  32. GUO Y, Zhang Y, Gerhard M, Gao JJ, et al
    Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer.
    Gut. 2019 Dec 19. pii: gutjnl-2019-319696. doi: 10.1136/gutjnl-2019-319696.
    PubMed     Abstract available


  33. COSTA L, Corre S, Michel V, Le Luel K, et al
    USF1 defect drives p53 degradation during Helicobacter pylori infection and accelerates gastric carcinogenesis.
    Gut. 2019 Dec 10. pii: gutjnl-2019-318640. doi: 10.1136/gutjnl-2019-318640.
    PubMed     Abstract available


    November 2019
  34. TONG H, Lan T, Tang CW
    Prophylactic angiographic embolisation after endoscopic treatment of bleeding for high-risk peptic ulcers: what are the more appropriate indications?
    Gut. 2019 Nov 27. pii: gutjnl-2019-319818. doi: 10.1136/gutjnl-2019-319818.
    PubMed    


    August 2019
  35. XIAO Y, Zhang S, Dai N, Fei G, et al
    Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
    Gut. 2019 Aug 13. pii: gutjnl-2019-318365. doi: 10.1136/gutjnl-2019-318365.
    PubMed     Abstract available


    May 2019
  36. DOORAKKERS E, Lagergren J, Engstrand L, Brusselaers N, et al
    Reply to: Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a western population.
    Gut. 2019 May 21. pii: gutjnl-2019-319000. doi: 10.1136/gutjnl-2019-319000.
    PubMed    


  37. GUO CG, Cheung KS, Zhang F, Chan EW, et al
    Incidences, temporal trends and risks of hospitalisation for gastrointestinal bleeding in new or chronic low-dose aspirin users after treatment for Helicobacter pylori: a territory-wide cohort study.
    Gut. 2019 May 17. pii: gutjnl-2019-318352. doi: 10.1136/gutjnl-2019-318352.
    PubMed     Abstract available


    February 2019

  38. Correction: Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018.
    Gut. 2019;68:380.
    PubMed    


    September 2018
  39. CHOI E, Lantz TL, Vlacich G, Keeley TM, et al
    Lrig1+ gastric isthmal progenitor cells restore normal gastric lineage cells during damage recovery in adult mouse stomach.
    Gut. 2018;67:1595-1605.
    PubMed     Abstract available


    July 2018
  40. CHUANG SC, Lin CC, Peng CY, Huang WH, et al
    Proton pump inhibitors increase the risk of cholecystitis: a population-based case-control study.
    Gut. 2018 Jul 17. pii: gutjnl-2018-316899. doi: 10.1136/gutjnl-2018-316899.
    PubMed    


  41. MOAYYEDI P, Veldhuyzen van Zanten SJO, Hookey L, Armstrong D, et al
    Proton pump inhibitors and gastric cancer: association is not causation.
    Gut. 2018 Jul 13. pii: gutjnl-2018-316958. doi: 10.1136/gutjnl-2018-316958.
    PubMed    


  42. LOFFROY R, Bardou M
    Prophylactic angiographic embolisation in high-risk peptic ulcer bleeding after achieved endoscopic control: maximising outcomes.
    Gut. 2018 Jul 11. pii: gutjnl-2018-316925. doi: 10.1136/gutjnl-2018-316925.
    PubMed    


  43. POTTER MDE, Wood NK, Walker MM, Jones MP, et al
    Proton pump inhibitors and suppression of duodenal eosinophilia in functional dyspepsia.
    Gut. 2018 Jul 7. pii: gutjnl-2018-316878. doi: 10.1136/gutjnl-2018-316878.
    PubMed    


    June 2018
  44. KAWAI T, Oda K, Funao N, Nishimura A, et al
    Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
    Gut. 2018;67:1033-1041.
    PubMed     Abstract available


    May 2018
  45. KOBAYASHI J, Uchida H, Ito J
    Long-term proton pump inhibitor use after Helicobacter pylori eradication may create a gastric environment for N-nitrosamine formation and gastric cancer development.
    Gut. 2018 May 25. pii: gutjnl-2018-316592. doi: 10.1136/gutjnl-2018-316592.
    PubMed    


  46. LAU JYW, Pittayanon R, Wong KT, Pinjaroen N, et al
    Prophylactic angiographic embolisation after endoscopic control of bleeding to high-risk peptic ulcers: a randomised controlled trial.
    Gut. 2018 May 25. pii: gutjnl-2018-316074. doi: 10.1136/gutjnl-2018-316074.
    PubMed     Abstract available


    April 2018
  47. SUNG JJ, Chiu PC, Chan FKL, Lau JY, et al
    Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018.
    Gut. 2018 Apr 24. pii: gutjnl-2018-316276. doi: 10.1136/gutjnl-2018-316276.
    PubMed     Abstract available


  48. LAI SW, Lai HC, Lin CL, Liao KF, et al
    Proton pump inhibitors and risk of gastric cancer in a case-control study.
    Gut. 2018 Apr 16. pii: gutjnl-2018-316371. doi: 10.1136/gutjnl-2018-316371.
    PubMed    


  49. WAN QY, Wu XT, Li N, Du L, et al
    Long-term proton pump inhibitors use and risk of gastric cancer: a meta-analysis of 926 386 participants.
    Gut. 2018 Apr 3. pii: gutjnl-2018-316416. doi: 10.1136/gutjnl-2018-316416.
    PubMed    


    February 2018
  50. PENG YC, Huang LR, Lin CL, Hsu WY, et al
    Association between proton pump inhibitors use and risk of gastric cancer in patients with GERD.
    Gut. 2018 Feb 22. pii: gutjnl-2018-316057. doi: 10.1136/gutjnl-2018-316057.
    PubMed    


    January 2018
  51. DOORAKKERS E, Lagergren J, Engstrand L, Brusselaers N, et al
    Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population.
    Gut. 2018 Jan 30. pii: gutjnl-2017-315363. doi: 10.1136/gutjnl-2017-315363.
    PubMed     Abstract available


  52. SUISSA S, Suissa A
    Proton-pump inhibitors and increased gastric cancer risk: time-related biases.
    Gut. 2018 Jan 3. pii: gutjnl-2017-315729. doi: 10.1136/gutjnl-2017-315729.
    PubMed    


    December 2017
  53. NIIKURA R, Hayakawa Y, Hirata Y, Yamada A, et al
    Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for Helicobacter pylori: a retrospective cohort analysis.
    Gut. 2017 Dec 22. pii: gutjnl-2017-315710. doi: 10.1136/gutjnl-2017-315710.
    PubMed    


  54. SUZUKI H, Matsuzaki J
    Helicobacter pylori eradication failure may have confounded the recent large-scale health database study that showed proton pump inhibitors increase gastric cancer risk.
    Gut. 2017 Dec 15. pii: gutjnl-2017-315698. doi: 10.1136/gutjnl-2017-315698.
    PubMed    


    November 2017
  55. GUETA I, Halkin H, Markovits N, Loebstein R, et al
    Proton pump inhibitors and the risk for gastric cancer: possible confounding by serum vitamin B 12.
    Gut. 2017 Nov 28. pii: gutjnl-2017-315695. doi: 10.1136/gutjnl-2017-315695.
    PubMed    


  56. WALDUM HL, Fossmark R
    Proton pump inhibitors and gastric cancer: a long expected side effect finally reported also in man.
    Gut. 2017 Nov 20. pii: gutjnl-2017-315629. doi: 10.1136/gutjnl-2017-315629.
    PubMed    


    October 2017
  57. CHEUNG KS, Chan EW, Wong AYS, Chen L, et al
    Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study.
    Gut. 2017 Oct 31. pii: gutjnl-2017-314605. doi: 10.1136/gutjnl-2017-314605.
    PubMed     Abstract available


  58. REVELES KR, Ryan CN, Chan L, Cosimi RA, et al
    Proton pump inhibitor use associated with changes in gut microbiota composition.
    Gut. 2017 Oct 9. pii: gutjnl-2017-315306. doi: 10.1136/gutjnl-2017-315306.
    PubMed    


  59. MIZOKAMI Y, Oda K, Funao N, Nishimura A, et al
    Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
    Gut. 2017 Oct 7. pii: gutjnl-2017-314010. doi: 10.1136/gutjnl-2017-314010.
    PubMed     Abstract available


    September 2017
  60. GRAHAM DY
    Illusions regarding Helicobacter pylori clinical trials and treatment guidelines.
    Gut. 2017 Sep 21. pii: gutjnl-2017-314744. doi: 10.1136/gutjnl-2017-314744.
    PubMed    


  61. NOTO JM, Chopra A, Loh JT, Romero-Gallo J, et al
    Pan-genomic analyses identify key Helicobacter pylori pathogenic loci modified by carcinogenic host microenvironments.
    Gut. 2017 Sep 18. pii: gutjnl-2017-313863. doi: 10.1136/gutjnl-2017-313863.
    PubMed     Abstract available


  62. HUO X, Agoston AT, Dunbar KB, Cipher DJ, et al
    Hypoxia-inducible factor-2alpha plays a role in mediating oesophagitis in GORD.
    Gut. 2017;66:1542-1554.
    PubMed     Abstract available


    August 2017
  63. VOHLONEN IJ, Hakama M, Harkonen M, Malila N, et al
    Oesophageal cancer incidence in 20-year follow-up in a population-based sample of 12 000 middle-age men with or without Helicobacter pylori infection in Finland.
    Gut. 2017 Aug 31. pii: gutjnl-2017-314913. doi: 10.1136/gutjnl-2017-314913.
    PubMed    


    June 2017
  64. MERA RM, Bravo LE, Camargo MC, Bravo JC, et al
    Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial.
    Gut. 2017 Jun 24. pii: gutjnl-2016-311685. doi: 10.1136/gutjnl-2016-311685.
    PubMed     Abstract available


  65. LIN PY, Tang JH, Chang CC
    A rare cause of GI bleeding in a 56-year-old man.
    Gut. 2017;66:1074.
    PubMed    


    May 2017
  66. SIERRA JC, Asim M, Verriere TG, Piazuelo MB, et al
    Epidermal growth factor receptor inhibition downregulates Helicobacter pylori-induced epithelial inflammatory responses, DNA damage and gastric carcinogenesis.
    Gut. 2017 May 4. pii: gutjnl-2016-312888. doi: 10.1136/gutjnl-2016-312888.
    PubMed     Abstract available


    April 2017
  67. HOUGHTON LA, Smith JA
    Gastro-oesophageal reflux events: just another trigger in chronic cough?
    Gut. 2017 Apr 25. pii: gutjnl-2017-314027. doi: 10.1136/gutjnl-2017-314027.
    PubMed    


  68. LORD AR, Simms LA, Hanigan K, Sullivan R, et al
    Protective effects of Helicobacter pylori for IBD are related to the cagA-positive strain.
    Gut. 2017 Apr 13. pii: gutjnl-2017-313805. doi: 10.1136/gutjnl-2017-313805.
    PubMed    


    February 2017
  69. EUSEBI LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, et al
    Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis.
    Gut. 2017 Feb 23. pii: gutjnl-2016-313589. doi: 10.1136/gutjnl-2016-313589.
    PubMed     Abstract available


    December 2016
  70. OTSUKA T, Sugimoto M, Inoue R, Ohno M, et al
    Influence of potassium-competitive acid blocker on the gut microbiome of Helicobacter pylori-negative healthy individuals.
    Gut. 2016 Dec 13. pii: gutjnl-2016-313312. doi: 10.1136/gutjnl-2016-313312.
    PubMed    


    October 2016
  71. MERCHANT JL
    NF-kappaB mediated transcription of DARPP-32 prevents Helicobacter pylori-induced cell death.
    Gut. 2016 Oct 27. pii: gutjnl-2016-312822. doi: 10.1136/gutjnl-2016-312822.
    PubMed    


  72. MALFERTHEINER P, Megraud F, O'Morain CA, Gisbert JP, et al
    Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.
    Gut. 2016 Oct 5. pii: gutjnl-2016-312288. doi: 10.1136/gutjnl-2016-312288.
    PubMed     Abstract available


    September 2016
  73. YEO YH, Shiu SI, Ho HJ, Zou B, et al
    First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis.
    Gut. 2016 Sep 26. pii: gutjnl-2016-311868. doi: 10.1136/gutjnl-2016-311868.
    PubMed     Abstract available


  74. MOLINA-INFANTE J, Hirano I, Spechler SJ
    Clarifying misunderstandings and misinterpretations about proton pump inhibitor-responsive oesophageal eosinophilia.
    Gut. 2016 Sep 13. pii: gutjnl-2016-312851. doi: 10.1136/gutjnl-2016-312851.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Peptic Ulcer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: